Felodipine–Metoprolol Combination Tablet: Maintained Health-Related Quality of Life in the Presence of Substantial Blood Pressure Reduction

Dahlöf, Björn; Innocenti, Alessio Deglʼ; Elmfeldt, Dag; Puig, Juan; Gundersen, T; Hosie, J.; Januszewicz, W; Lindström, Carl-Johan; Magometschnigg, D; Tanser, Paul H.; Toutouzas, P.; Waeber, B

doi:10.1016/j.amjhyper.2005.04.017

Cited by 18 publications

(22 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…recent data suggest that patients with established hypertension receiving pharmacotherapy may feel better as blood pressure is lowered because of symptom improvement, regardless of the type of medication given. 2,15 angiotensin-converting enzyme inhibitors and angiotensin ii receptor antagonists may offer some advantage with regard to effects on cognitive function and sexual activity 16 ; one study has also suggested that a calcium channel blocker-based treatment regimen lowered the incidence of dementia.…”

Section: Boi Analysismentioning

confidence: 99%

An Evaluation of the Effects of an Angiotensin Receptor Blocker on Health‐Related Quality of Life in Patients With High‐Normal Blood Pressure (Prehypertension) in the Trial of Preventing Hypertension (TROPHY)

Williams

Michelson

Cain

et al. 2008

J of Clinical Hypertension

View full text Add to dashboard Cite

The Trial of Preventing Hypertension (TROPHY) demonstrated the feasibility of possibly reducing the incidence of hypertension with the angiotensin receptor blocker candesartan compared with placebo. The long‐term benefits of pharmacologic therapy in high‐normal blood pressure, or prehypertension are not known, and the long‐term effect on health‐related quality of life (HRQL) has not been determined. An analysis of covariance model was used to assess treatment differences from baseline in the HRQL scores using Short Form (SF)‐36, and component measures at subsequent visits. Of the 809 randomized patients, 734 had both baseline and ≥1 HRQL follow‐up assessment: 95% (379 of 397) of patients receiving candesartan and 91% (355 of 388) of patients receiving placebo. There were no statistically significant between‐group differences in least‐squares mean physical component survey and mental component survey scores or the individual scales at each scheduled visit relative to baseline values (P >.05). In TROPHY, patients with prehypertension had relatively high baseline HRQL, and HRQL was maintained with the angiotensin receptor blocker candesartan over both the 2‐year treatment period and a total 4‐year trial period.

show abstract

Section: Boi Analysismentioning

confidence: 99%

An Evaluation of the Effects of an Angiotensin Receptor Blocker on Health‐Related Quality of Life in Patients With High‐Normal Blood Pressure (Prehypertension) in the Trial of Preventing Hypertension (TROPHY)

Williams

Michelson

Cain

et al. 2008

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

“…Such a favorable finding agrees with a previous report. 24 There were no significant side-effects in both treatment groups. However, BNP significantly increased in the betaxolol adding group after 6 months of treatment.…”

Section: Discussionmentioning

confidence: 94%

Comparative Effects of Amlodipine Monotherapy and Combination Therapy With Betaxolol on Cardiac Autonomic Nervous Activity and Health-Related Quality of Life in Patients With Poorly Controlled Hypertension

Takase

Takeishi

Hirai

et al. 2008

Circ J

View full text Add to dashboard Cite

ong-acting calcium channel blockers are being frequently used for the treatment of hypertension in clinical practice. In particular, amlodipine is one of the most prescribed drugs of long-acting calcium channel blockers. [1][2][3] According to the guidelines for the management of hypertension (JSH 2004), the combined treatment of long-acting calcium channel blockers and -blockers is recommended. 4 Betaxolol, a third generation -blocker, is characterized as being long-acting, 1-adrenoceptor selective antagonist with a mild vasodilator effect and has few effects on metabolism of carbohydrates and lipids. [5][6][7][8] It is assumed that calcium channel blockers and -blockers, could have synergistic effects on blood pressure (BP) decrease and prevent a reflex tachycardia caused by the calcium channel blockers.Heart rate variability (HRV) indexes are well known prognostic markers for the various cardiovascular disorders, including hypertensive patients. [9][10][11][12][13][14] It is likely that the combined treatment of calcium channel blockers and -blockers might have a beneficial effect on cardiac autonomic nervous activity (CANA) assessed by HRV. However, there are no studies to directly compare the dose-up effect of amlodipine with the adding effect of betaxolol on CANA in patients with low dose amlodipine therapy.Antihypertensive drug therapy might elicit adverse drug reactions and compromise the patient's health-related quality of life (HRQL). 15,16 Particularly, -blockers might be associated with symptoms such as fatigability and inactivity.Thus, the purpose of the present study was to evaluate whether betaxolol adding therapy could have better outcomes of CANA assessed by HRV and HRQL evaluated by the questionnaire sheets than amlodipine dose-up therapy in patients with a poor BP control with low dose amlodipine therapy. Methods Study PopulationThe study population consisted of 65 hypertensive patients (66±9 years, 36 men and 29 women) who were Circ J 2008; 72: 764 -769

show abstract

“…Significant differences in HRQL scores between treatments were observed in our study. Recent data [12,13] suggest that patients with established hypertension receiving pharmacotherapy may feel better as blood pressure is lowered because of symptoms improvement, regardless of the type of the medication given. The current study's results are consistent with previous studies evaluating the effect of antihypertensive medications on HRQL.…”

Section: Discussionmentioning

confidence: 99%

Quality Of Life of Hypertensive Patients on Different Types of Antihypertensive Medications

Shanableh¹

2014

iosrphr

View full text Add to dashboard Cite

: More than three quarter of the total death in the UAE is due to cardiovascular diseases. Health Related Quality of Life (HRQL) is a broad multidimensional concept that usually includes 3% of hypertensive patients used a combination therapy of two medicines; 33% used Angiotensin receptor blockers (ARB) + Diuretics and 20% used the combination of B-blockers + Diuretics. Only 6% of the patients used B-Blockers class for their treatment. Data were analyzed by SPSS. The mean values of Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (V), Social Functioning (SF), Role Emotional (RE), Mental Health (MH), Physical Components Summary (PCS), and Mental Components Summary (MCS) scores were 62.5, 62.9, 72.1, 62.1, 64.5, 76.7, 68.8, 66.2, 47.0, and 47.8

show abstract

Felodipine–Metoprolol Combination Tablet: Maintained Health-Related Quality of Life in the Presence of Substantial Blood Pressure Reduction

Abstract: The HRQL is maintained in the presence of substantial BP reduction during antihypertensive treatment with F+M fixed combination tablets.

Cited by 18 publications

References 22 publications

An Evaluation of the Effects of an Angiotensin Receptor Blocker on Health‐Related Quality of Life in Patients With High‐Normal Blood Pressure (Prehypertension) in the Trial of Preventing Hypertension (TROPHY)

An Evaluation of the Effects of an Angiotensin Receptor Blocker on Health‐Related Quality of Life in Patients With High‐Normal Blood Pressure (Prehypertension) in the Trial of Preventing Hypertension (TROPHY)

Comparative Effects of Amlodipine Monotherapy and Combination Therapy With Betaxolol on Cardiac Autonomic Nervous Activity and Health-Related Quality of Life in Patients With Poorly Controlled Hypertension

Quality Of Life of Hypertensive Patients on Different Types of Antihypertensive Medications

Contact Info

Product

Resources

About